Azepinone as a conformational constraint in the design of κ-opioid receptor agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 22, 2004, Pages 5693-5697

  Tuthill, Paul A ^a   Seida, Pamela R ^a   Barker, William ^a   Cassel, Joel A ^a   Belanger, Serge ^a   DeHaven, Robert N ^a   Koblish, Michael ^a   Gottshall, Susan L ^a   Little, Patrick J ^a   DeHaven Hudkins, Diane L ^a   Dolle, Roland E ^a  

^a ADOLOR CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [1 PHENYL 2 (1 PYRROLIDINYL)ETHYL]BENZENEACETAMIDE; ACETAMIDE DERIVATIVE; AZEPINONE; KAPPA OPIATE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANTINOCICEPTION; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG CONFORMATION; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; MOUSE; NONHUMAN; RAT; REACTION ANALYSIS; SEDATION; STRUCTURE ACTIVITY RELATION;

ACETIC ACID; ANIMALS; AZEPINES; BINDING SITES; DRUG DESIGN; FORMALDEHYDE; LIGANDS; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PAIN MEASUREMENT; RATS; RECEPTORS, OPIOID, KAPPA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

RODENTIA;

EID: 5144224991     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.08.041     Document Type: Article

References (29)

1. D.I.C. Scopes Exp. Opin. Invest. Drugs 3 1994 369 376
2. B.N. Dhawan, F. Cesselin, R. Raghubir, T. Reisine, P.B. Bradley, P.S. Portoghese, and M. Hamon Pharmacol. Rev. 48 1996 567 592
3. A. Barber, and R. Gottschlich Exp. Opin. Invest. Drugs 6 1997 1351 1368
4. G.F. Costello, B.G. Main, J.J. Barlow, J.A. Carroll, and J.S. Shaw Eur. J. Pharmacol. 151 1988 475 478
5. P.F. Von Voigtlander, R.A. Lahti, and J.H. Ludens J. Pharmacol. Exp. Ther. 224 1983 7 12
6. R.A. Dionne, K.R. Dobbins, and K.M. Hargreaves Clin. Pharmacol. Ther. 49 1991 183
7. A.C. Pande, R.E. Pyke, M. Greiner, S.A. Cooper, R. Benjamin, and M.W. Pierce Clin. Neuropharmacol. 19 1996 92 97
8. A.C. Pande, R.E. Pyke, M. Greiner, G.L. Wideman, R. Benjamin, and M.W. Pierce Clin. Neuropharmacol. 19 1996 451 456
9. Q. Zhang, M. Schafer, R. Elde, and C. Stein Neuroscience 85 1998 281 291
10. For a review regarding peripherally acting opioid agonists as analgesics, see: D.L. DeHaven-Hudkins, and R.E. Dolle Curr. Pharm. Des. 10 2004 743 757
11. J.C. Eisenach, R. Carpenter, and R. Curry Pain 101 2003 89 95
12. V. Kumar, M.A. Marella, L. Cortes-Burgos, A.-C. Chang, J.A. Cassel, J.D. Daubert, R.N. DeHaven, D.L. DeHaven-Hudkins, S.L. Gottshall, E. Mansson, and A.L. Maycock Bioorg. Med. Chem. Lett. 10 2000 2567 2570
13. G.F. Costello, R. James, J.S. Shaw, A.M. Slater, and N.C.J. Stutchbury J. Med. Chem. 34 1991 181 189
14. For the crystal structure of 1, see: G. Subramanian, M.G. Paterlini, D.L. Larson, P.S. Portoghese, and D.M. Ferguson J. Med. Chem. 41 1998 4777 4789
15. Tuthill, P. A., Sr.; Seida, P.; Dolle, R. E.; Cassel, J. A.; DeHaven, R. N. Abstracts of Papers, 226th ACS National Meeting, New York, NY, September 7-11, 2003, MEDI 151
16. To ensure chiral integrity, diamine 8 was acylated with 2-naphthoyl chloride. The corresponding amide was then subjected to chiral HPLC analysis (Chiralpak AD) and was determined to be 96% ee, indicating that no significant racemization had occurred at the carbon atom bearing the phenyl ring
17. (a)All new compounds showed physical and spectroscopic properties consistent with their structures
18. 3 (400 MHz) δ 7.75 (1H, br s), 7.73 (1H, d, J = 7.8 Hz), 7.64 (1H, d, J = 7.6 Hz), 7.52 (1H, t, J = 7.8 Hz), 7.35-7.25 (5H, m), 6.04 (1H, br t, J = 7.6 Hz), 5.68 (1H, m), 5.43 (1H, m), 4.49 (1H, d, J = 11.7 Hz), 4.25 (1H, d, J = 17.4 Hz), 3.36 (1H, dd, J = 7.6, 17.40 Hz), 3.29-3.23 (4H, m), 3.03 (1H, t, J = 10.7 Hz), 2.84 (2H, m), 2.63 (2H, s), 2.50 (3H, m), 1.77-1.71 (8H, m); LCMS m/z 494.3 (M+1)
19. 1H NMRs of the intermediate dienes were rather complex, the presence of rotomers notwithstanding, indicating a mixture of diastereomers. In one case, the mixture of dienes was separated and the major diene diastereomer so obtained was subjected to the ring closing metathesis reaction, affording exclusively the syn-product (unpublished observation); hence, the metathesis reaction was racemization free
20. For a review on kinetic resolution strategies using non-enzymatic catalysts, see: D.E.J.E. Robinson, and S.D. Bull Tetrahedron: Asymmetry 14 2003 1407 1446
21. H. Li, X. Jiang, Y.-H. Ye, C. Fan, T. Romoff, and M. Goodman Org. Lett. 1 1999 91 93
22. Acid 16 required for 15 was prepared from allyl 3,4- dichlorophenoxyacetate 17 via the enolate Claisen rearrangement using the method of Burke: S.D. Burke, W.F. Fobare, and G.J. Pacofsky J. Org. Chem. 48 1993 5221 5228
23. 50 = 50 nM
24. The 3-hydroxy analog 18 of 4a was prepared. The hydroxy group is known to enhance receptor affinity for κ: R. Gottschlich, K.A. Ackermann, A. Barber, G.D. Bartoszyk, and H.E. Greiner Bioorg. Med. Chem. Lett. 4 1994 677 682
25. The RCM reaction proved to be a versatile reaction and was used to prepare higher order lactams, for example, 19.
26. R.N. DeHaven, and D.L. DeHaven-Hudkins S.J. Enna M. Williams J.W. Ferkany T. Kenakin R.D. Porsolt J.P. Sullivan Current Protocols in Pharmacology 1998 John Wiley and Sons New York 1.4.1 1.4.12
27. In vivo test methods: (a) Acetic acid-induced writhing: Mice were treated with vehicle or compound 4a and 15 min later injected with 0.6% acetic acid intraperitoneally. Five minutes after the administration of acetic acid, the number of writhes was counted for a 10 min period
28. P. Horan, B.R. de Costa, K.C. Rice, and F.J. Porreca J. Pharmacol. Exp. Ther. 257 1991 1154 1161 Briefly, mice were placed on a raised plastic platform (11 x 7.5 x 3 cm) and the latency to completely step off the platform was determined before (baseline sedation latency) and 30 min after drug treatment. Mice with baseline sedation latencies of 15 s or greater were not used. After the drug treatment, a 30 s cut-off was used for the latency to step off the platform
29. Formalin-induced flinching: Late phase formalin-induced flinching was determined using the method of D.L. DeHaven-Hudkins, L. Cortes Burgos, J.A. Cassel, J.D. Daubert, R.N. DeHaven, E. Mansson, H. Nagasaka, G. Yu, and T. Yaksh J. Pharmacol. Exp. Ther. 289 1999 494 502